Premium
Deletion of macrophage migration inhibitory factor inhibits murine oral carcinogenesis: Potential role for chronic pro‐inflammatory immune mediators
Author(s) -
Oghumu Steve,
Knobloch Thomas J.,
Terrazas Cesar,
Varikuti Sanjay,
AhnJarvis Jennifer,
Bollinger Claire E.,
Iwenofu Hans,
Weghorst Christopher M.,
Satoskar Abhay R.
Publication year - 2016
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.30177
Subject(s) - macrophage migration inhibitory factor , immune system , carcinogenesis , macrophage , immunology , inflammation , inhibitory postsynaptic potential , biology , cancer research , medicine , cytokine , cancer , in vitro , genetics , endocrinology
Oral cancer kills about 1 person every hour each day in the United States and is the sixth most prevalent cancer worldwide. The pro‐inflammatory cytokine ‘macrophage migration inhibitory factor’ (MIF) has been shown to be expressed in oral cancer patients, yet its precise role in oral carcinogenesis is not clear. In this study, we examined the impact of global Mif deletion on the cellular and molecular process occurring during oral carcinogenesis using a well‐established mouse model of oral cancer with the carcinogen 4‐nitroquinoline‐1‐oxide (4NQO). C57BL/6 Wild‐type (WT) and Mif knock‐out mice were administered with 4NQO in drinking water for 16 weeks, then regular drinking water for 8 weeks. Mif knock‐out mice displayed fewer oral tumor incidence and multiplicity, accompanied by a significant reduction in the expression of pro‐inflammatory cytokines Il ‐1β, Tnf ‐α, chemokines Cxcl1 , Cxcl6 and Ccl3 and other molecular biomarkers of oral carcinogenesis Mmp1 and Ptgs2 . Further, systemic accumulation of myeloid‐derived tumor promoting immune cells was inhibited in Mif knock‐out mice. Our results demonstrate that genetic Mif deletion reduces the incidence and severity of oral carcinogenesis, by inhibiting the expression of chronic pro‐inflammatory immune mediators. Thus, targeting MIF is a promising strategy for the prevention or therapy of oral cancer.